Pfizer Acquires TransTech RAGE Compounds
This article was originally published in The Pink Sheet Daily
Executive Summary
TransTech Pharma’s receptor for advanced glycation end products antagonists have potential to treat Alzheimer’s disease.
You may also be interested in...
Keryx Looks To Release Top-Line Sulonex Phase III Data Early Next Year
A 2008 launch of the first-in-class diabetic nephropathy treatment is possible.
Keryx Looks To Release Top-Line Sulonex Phase III Data Early Next Year
A 2008 launch of the first-in-class diabetic nephropathy treatment is possible.
Novo Nordisk Licenses GKA Program To Innovator TransTech
Deal is part of Novo’s effort to focus on protein-based molecules.